Does Study Design Influence Outcome?
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Background: Clinicians and researchers synthesize data from randomized controlled trials (RCTs) of antidepressants to make conclusions about the efficacy of medications for depression. All treatments include nonspecific factors in addition to the specific effects of drugs, and study design may influence patient outcomes via nonspecific factors. This study investigated whether placebo control and treatment duration affect the outcome in antidepressant RCTs. Methods: Medline and the Cochrane Database were searched to identify RCTs of antidepressants for major depression approved by the Food and Drug Administration. Included studies enrolled outpatient participants aged 18–65, lasted 6–12 weeks, compared an antidepressant to placebo or another antidepressant and were published in English after 1985. Excluded trials enrolled inpatients, pregnant women and subjects with psychosis or mania. Mixed-effects logistic regression models including study type (placebo-controlled or comparator) and study duration (6, 8 or 12 weeks) as fixed effects determined whether these factors affected response and remission rates. Results: In the 90 trials analyzed, the odds of depression response (OR = 1.79, 95% CI = 1.45–2.17, p < 0.001) and remission (OR 1.53, 95% CI = 1.11–2.11, p < 0.001) were significantly higher in comparator relative to placebo-controlled trials. Trials lasting 8 (OR = 1.37, CI = 1.14–1.64, p = 0.001) and 12 (OR = 1.52, CI = 1.12–2.07, p = 0.008) weeks had significantly greater response rates than 6-week trials without differing themselves. Conclusions: Response and remission rates to antidepressants are significantly affected by study type and duration. Clinicians and researchers must consider the study design when interpreting and designing RCTs of antidepressant medications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Assessing the quality of controlled clinical trials
Jüni, P., Altman, D. G., & Egger, M. (2001) · BMJ · doi:10.1136/bmj.323.7303.42 · Cited by 3,309
Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050045 · Cited by 2,442
Keller, M. B., McCullough, J. P., Klein, D. N., Arnow, B., Dunner, D. L., Gelenberg, A. J., Markowitz, J. C., Nemeroff, C. B., Russell, J. M., Thase, M. E., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422001 · Cited by 1,331
Placebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109
Residual symptoms after partial remission: an important outcome in depression
Paykel, E. S., Ramana, R., Cooper, Z., Hayhurst, H., Kerr, J., & Barocka, A. (1995) · Psychological Medicine · doi:10.1017/s0033291700033146 · Cited by 791 · cited 1×
“recently examined antidepressant response rates in 9 placebo-controlled and 7 comparator trials for late-life depression. A 46p response rate to medication was found in placebo-controlled trials compared to 63p in comparator trials. The odds of medication response in comparator trials were nearly 2 times the odds in p…”
BackgroundInfluentialReport by the ACNP Task Force on Response and Remission in Major Depressive Disorder
Rush, A. J., Kraemer, H. C., Sackeim, H. A., Fava, M., Trivedi, M. H., Frank, E., Ninan, P. T., Thase, M. E., Gelenberg, A. J., Kupfer, D. J., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301131 · Cited by 707
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.8.997 · Cited by 580
Khan, A., Leventhal, R. M., Khan, S. R., & Brown, W. A. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200202000-00007 · Cited by 456
Detke, M. J., Lu, Y., Goldstein, D. J., Hayes, J. R., & Demitrack, M. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0407 · Cited by 384
Duloxetine in the Treatment of Major Depressive Disorder: A Double-Blind Clinical Trial
Goldstein, D. J., Mallinckrodt, C., Lu, Y., & Demitrack, M. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0309 · Cited by 334
Goldstein, D. J., Lu, Y., Detke, M. J., Wiltse, C., Mallinckrodt, C., & Demitrack, M. A. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000132448.65972.d9 · Cited by 314
Residual symptoms at remission from depression: Impact on long-term outcome
Kennedy, N., & Paykel, E. S. (2004) · Journal of Affective Disorders · doi:10.1016/s0165-0327(03)00054-5 · Cited by 199
Bielski, R. J., Ventura, D., & Chang, C.-C. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0906 · Cited by 178
Montgomery, S. A., Huusom, A. K. T., & Bothmer, J. (2004) · Neuropsychobiology · doi:10.1159/000078225 · Cited by 168
A Comparison of Venlafaxine, Trazodone, and Placebo in Major Depression
CUNNINGHAM, L. A., BORISON, R. L., CARMAN, J. S., CHOUINARD, G., CROWDER, J. E., DIAMOND, B. I., FISCHER, D. E., & HEARST, E. (1994) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199404000-00003 · Cited by 159
Rudolph, R. L., & Feiger, A. D. (1999) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00067-1 · Cited by 158
Dieric, M., Ravizza, U., Realini, R., & Martin, A. (1996) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(95)00292-8 · Cited by 152
Leinonen, E., Skarstein, J., Behnke, K., ??gren, H., & Th Helsdingen, J. (1999) · International Clinical Psychopharmacology · doi:10.1097/00004850-199911000-00002 · Cited by 146
Sneed, J. R., Rutherford, B. R., Rindskopf, D., Lane, D. T., Sackeim, H. A., & Roose, S. P. (2008) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181256b1d · Cited by 140 · cited 1×
“However, they did not conduct a formal literature search, provide inclusion and exclusion criteria for the studies they examined or test whether the observed difference was statistically significant.Sneed et al. [”
BackgroundSelf-citationContinuation and Maintenance Use of Antidepressants in Recurrent Depression
Bockting, C. L. H., ten Doesschate, M. C., Spijker, J., Spinhoven, P., Koeter, M. W. J., & Schene, A. H. (2008) · Psychotherapy and Psychosomatics · doi:10.1159/000110056 · Cited by 121
Increase in Antidepressant Medication in the US Adult Population between 1990 and 2003
Mojtabai, R. (2008) · Psychotherapy and Psychosomatics · doi:10.1159/000112885 · Cited by 100 · cited 1×
“analyzed data from 47 RCTs of antidepressants submitted to the FDA for marketing approval, finding a mean improvement of 9.60 points on the HRSD in the drug group compared to 7.80 in the placebo groups. The response to placebo therefore duplicated >80p of the change found in the drug groups, and the difference between…”
InfluentialHicks, J. A., Argyropoulos, S. V., Rich, A. S., Nash, J., Bell, C. J., Edwards, C., Nutt, D. J., & Wilson, S. J. (2002) · British Journal of Psychiatry · doi:10.1192/bjp.180.6.528 · Cited by 84
BYERLEY, W. F., REIMHERR, F. W., WOOD, D. R., & GROSSER, B. I. (1988) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198804000-00005 · Cited by 80
A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder
Chouinard, G., Saxena, B., Bélanger, M.-C., Ravindran, A., Bakish, D., Beauclair, L., Morris, P., Vasavan Nair, N. P., Manchanda, R., Reesal, R., et al. (1999) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00188-8 · Cited by 57
A comparison of paroxetine and placebo in depressed outpatients
Dunbar, G. C., Claghorn, J. L., Kiev, A., Rickels, K., & Smith, W. T. (1993) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1993.tb03376.x · Cited by 42
Cited by
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
Chan, A.-W., Tetzlaff, J. M., Gotzsche, P. C., Altman, D. G., Mann, H., Berlin, J. A., Dickersin, K., Hrobjartsson, A., Schulz, K. F., Parulekar, W. R., et al. (2013) · BMJ · doi:10.1136/bmj.e7586 · Cited by 6,251
The placebo response in medicine: minimize, maximize or personalize?
Enck, P., Bingel, U., Schedlowski, M., & Rief, W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3923 · Cited by 671
Segal, Z. V., Bieling, P., Young, T., MacQueen, G., Cooke, R., Martin, L., Bloch, R., & Levitan, R. D. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.168 · Cited by 429
Locher, C., Koechlin, H., Zion, S. R., Werner, C., Pine, D. S., Kirsch, I., Kessler, R. C., & Kossowsky, J. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.2432 · Cited by 360
Schedlowski, M., Enck, P., Rief, W., & Bingel, U. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009423 · Cited by 323
Metadata
- Authors
- Rutherford, B. R., Sneed, J. R., & Roose, S. P.
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2009
- Volume
- 78
- Issue
- 3
- Pages
- 172-181
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W1989468762
- Cited by
- 158
- References
- 27
- FWCI
- 8.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.